| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 12.02.
| Spectrum Pharmaceuticals is Among the Companies in the Biotechnology Industry With the Lowest EBITDA Growth | | 5 | SmarTrend |
| 07.02.
| Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference | | 35 | Business Wire |
| Corporate Overview to be Presented on Tuesday, February 14th
at 3:30pm Eastern Time
Spectrum Pharmaceuticals (NasdaqGS:SPPI), a biotechnology...
Mehr lesen zu:
Spectrum Pharmaceuticals to Present at the BIO CEO Investor Conference | |
| 31.01.
| Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting GCSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals | | 51 | Business Wire |
| SPI-2012, Spectrum's Third Biological Drug, Is a Long-Acting GCSF
That Utilizes Hanmi's Proprietary Platform Technology, LAPSCOVERY™;
SPI-2012...
Mehr lesen zu:
Spectrum Pharmaceuticals In-Licenses a Novel, Long-Acting GCSF Drug in U.S. Clinical Trials from Hanmi Pharmaceuticals | |
| 27.01.
| Uptrend Call Working As Spectrum Pharmaceuticals Stock Rises 64.5% | | 5 | SmarTrend |
| 27.01.
| Spectrum Pharma: Solid Tech, Solid Fundamentals, Explosive Growth | | 3 | Seeking Alpha |
| 27.01.
| Spectrum Pharmaceuticals Strengthens Commercial Operations; Spectrum Expects Fourth Quarter 2011 Revenues to Be Equal to or Greater Than Third Quarter 2011 | | 2 | Benzinga.com |
| 27.01.
| Spectrum Pharmaceuticals Strengthens Commercial Operations | | 102 | Business Wire |
| Spectrum Expects Fourth Quarter 2011 Revenues to Be Equal to or
Greater Than Third Quarter 2011;
The Company Anticipates Filing Two New Drug...
Mehr lesen zu:
Spectrum Pharmaceuticals Strengthens Commercial Operations | |
| 27.01.
| Spectrum Pharma's Loss Is A Great Opportunity | | 5 | Seeking Alpha |
| 25.01.
| Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN® | | 35 | Business Wire |
| Spectrum's Commercial Footprint Expands Beyond the U.S.;
Irrevocable License From Bayer Healthcare Leverages Spectrum's
Existing Clinical, Regulatory...
Mehr lesen zu:
Spectrum Pharmaceuticals to Acquire Worldwide Rights to Market ZEVALIN® | |
| 23.01.
| Bullish Moving Average Cross by Spectrum Pharmaceuticals | | 3 | SmarTrend |
| 17.01.
| Shares of Spectrum Pharmaceuticals Rank the Lowest in Terms of Debt-to-Capital Ratio in the Biotechnology Industry | | - | SmarTrend |
| 12.01.
| Spectrum Pharmaceuticals Looks to Continue to Trade Above its Annual-High Share Price Today | | 3 | SmarTrend |
| 05.01.
| Spectrum Pharmaceuticals Shares Up 63.8% Since SmarTrend's Buy Recommendation | | 2 | SmarTrend |
| 05.01.
| Uptrend Call Working As Spectrum Pharmaceuticals Stock Rises 64.3% | | 1 | SmarTrend |
| 05.01.
| 64.5% Return Seen to Date on SmarTrend Spectrum Pharmaceuticals Call | | - | SmarTrend |
| 04.01.
| Uptrend Call Working As Spectrum Pharmaceuticals Stock Rises 65.5% | | - | SmarTrend |
| 04.01.
| Spectrum Pharmaceuticals to Present at the J. P. Morgan Healthcare Conference | | 52 | Business Wire |
| Corporate Overview to be Presented on Thursday, January 12th
at 11am Pacific Time at the 30th Annual
Conference in San Francisco, California
...
Mehr lesen zu:
Spectrum Pharmaceuticals to Present at the J. P. Morgan Healthcare Conference | |
| 04.01.
| Spectrum Pharmaceuticals Up 67.2% Since SmarTrend Uptrend Call | | - | SmarTrend |
| 02.01.
| Spectrum Pharmaceuticals Shares Up 66.3% Since SmarTrend's Buy Recommendation | | 1 | SmarTrend |
| 02.01.
| Spectrum Pharmaceuticals Up 66.3% Since SmarTrend Uptrend Call | | 1 | SmarTrend |
